NextRNA Therapeutics Company Profile

Background

NextRNA Therapeutics is a biotechnology company dedicated to developing transformative medicines targeting long non-coding RNAs (lncRNAs) implicated in various diseases, primarily focusing on oncology and neuroscience. The company's mission is to translate pioneering science into therapies that address unmet medical needs by inhibiting the function of lncRNAs through small molecule interventions.

Key Strategic Focus

NextRNA's strategic focus centers on:

Therapeutic Areas: Primarily oncology and neuroscience.

Technological Approach: Developing small molecules that disrupt lncRNA interactions with RNA-binding proteins (RBPs), thereby inhibiting pathological processes.

Platform Capabilities: Utilizing a proprietary platform that combines computational tools with deep lncRNA biology expertise to identify and validate disease-relevant lncRNA targets.

Financials and Funding

Since its inception in January 2021, NextRNA has secured significant funding:

Seed Financing: $9.3 million.

Series A Financing: $46.8 million, led by Cobro Ventures and Lightchain Capital, with participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors.

These funds are allocated to enhance the company's target and drug discovery engine, expand its pipeline, and advance lead programs.

Pipeline Development

NextRNA is advancing two lead programs:

1. Oncology Program: A lncRNA-targeting small molecule program in early preclinical development.
2. Neuroscience Program: Focused on addressing lncRNA-driven diseases within the central nervous system.

Additionally, in August 2024, NextRNA entered a collaboration with Bayer to jointly develop two oncology programs targeting lncRNAs.

Technological Platform and Innovation

NextRNA's proprietary platform is distinguished by:

NextMap™ Computational Engine: Facilitates the identification of tissue-specific and disease-driving lncRNAs across therapeutic areas.

lncRNA-RBP Interaction Disruption: Develops small molecules to inhibit lncRNA function by disrupting interactions with RBPs, offering flexibility to target either component of the interaction.

Leadership Team

Dominique Verhelle, PhD, MBA: Co-Founder & CEO. Over 20 years of industry experience, including roles at Takeda’s Center for External Innovation and Third Rock Ventures.

JS Cleiftie, MS, MBA: Chief Business Officer & Chief Financial Officer. Former Chief Business Officer at Erytech Pharma, with 20 years in business and corporate development.

Jesse Smith, PhD: Chief Scientific Officer. Appointed in September 2024, bringing over 20 years of drug discovery and development experience, including leadership roles at Civetta Therapeutics and Remix Therapeutics.

Leadership Changes

September 2024: Appointment of Jesse Smith, PhD, as Chief Scientific Officer.

December 2024: Appointment of Charles Kunsch, PhD, to the Board of Directors.

Competitor Profile

Market Insights and Dynamics

The lncRNA therapeutics market is emerging, with increasing recognition of lncRNAs as potential therapeutic targets across various diseases, including oncology and neuroscience.

Competitor Analysis

Key competitors include:

LncRNA Therapeutics Inc.: Focuses on antisense oligonucleotide therapies targeting lncRNAs.

RNA Biotech Ltd.: Develops RNA-based therapeutics, including those targeting non-coding RNAs.

Strategic Collaborations and Partnerships

Bayer Collaboration: In August 2024, NextRNA entered a collaboration and license agreement with Bayer to develop small molecule therapeutics targeting lncRNAs in oncology. The agreement includes up to $547 million in payments to NextRNA, encompassing upfront and milestone payments, research funding, and tiered royalties on net sales.

Operational Insights

NextRNA's strategic considerations include:

Differentiated Approach: Targeting lncRNA-RBP interactions with small molecules offers a novel therapeutic avenue distinct from competitors focusing on coding RNAs or protein targets.